Concepedia

Pascal Deschatelets

PD

Statistics

Publications

19

Citations

2.5K

H-Index

16

Active since

2001

Affiliations

Apellis Pharmaceuticals (United States)(Current)

Prince of Wales Hospital

Duke University

Chinese University of Hong Kong

Harvard University

Pascal Deschatelets is an author at Apellis Pharmaceuticals (United States) specializing in pharmacology, medicine, and clinical pharmacology.

ORCID

Publications per year

2001–2025

19

Publications

19

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration

David Liao, F Grossi, Delphine El Mehdi et al. · Ophthalmology · 2019 · 512 citations · Full text

, , +17

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Jeffrey S. Heier, Eleonora M. Lad, Frank G. Holz et al. · The Lancet · 2023 · 443 citations · Full text

, , +7

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, Jeff Szer, Ilene C. Weitz et al. · New England Journal of Medicine · 2021 · 385 citations · Full text

, , +17

Kosmotropes Form the Basis of Protein-Resistant Surfaces

Ravi S. Kane, Pascal Deschatelets, George M. Whitesides · Langmuir · 2003 · 325 citations

, , +17

Designing a polyvalent inhibitor of anthrax toxin

Michaël Mourez, Ravi S. Kane, Jeremy Mogridge et al. · Nature Biotechnology · 2001 · 272 citations

, , +12

1–5 of 19